modelRhenium186reEtidronicAci

Extends from Pharmacolibrary.Drugs.ATC.V.V10BX03.

Information

name:Rhenium186reEtidronicAcid
ATC code:V10BX03
route:intravenous
compartments:2
dosage:1295mg
volume of distribution:0.5L
clearance:0.17L/h/kg
other parameters in model implementation

Rhenium (186Re) etidronic acid is a radiopharmaceutical agent that consists of the radioactive isotope rhenium-186 complexed with etidronic acid (a bisphosphonate). It is primarily used for the palliative treatment of pain associated with bone metastases, particularly in cancer patients (e.g., prostate or breast cancer). The drug is not widely approved, but has seen investigational or limited use in several countries.

Pharmacokinetics

Pharmacokinetic estimates are based on published data from administration in adult cancer patients with painful bone metastases. These parameters reflect average values reported in the literature for this population.

References

    Parameters

    TypeNameDefaultDescription
    Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
    Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
    Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
    Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
    Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
    Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
    Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
    Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
    IntegeradminCount (from PK_1C)8number of dose administered (1)
    Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
    Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
    Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
    Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
    Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
    Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
    Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

    Connectors

    TypeNameDefaultDescription
    Types.ConcentrationOutputC_central (from PK_1C)
    Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
    Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
    Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

    Components

    TypeNameDefaultDescription
    Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
    Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
    Sources.PeriodicDoseperiodicDose (from PK_1C)
    Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
    Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
    Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

    Revisions

    • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)